herpes simplex virus type 1 glycoprotein gC

MW 130,000

Also Known As:

glycoprotein gC, herpes simplex virus type 1; HSV glycoprotein C; HSV type 1 glycoprotein gC; HSV-1 gC-1; HSV-I glycoprotein C; glycoprotein C; glycoprotein C, herpes simplex virus-1; herpes simplex virus type-1 glycoprotein gC

Networked: 82 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boyle, David S: 4 articles (01/2021 - 01/2014)
2.	Brindle, Eleanor: 3 articles (01/2021 - 01/2014)
3.	Barney, Rebecca: 2 articles (01/2021 - 01/2017)
4.	Hess, Sonja Y: 2 articles (01/2021 - 01/2017)
5.	Lillis, Lorraine: 2 articles (01/2021 - 01/2017)
6.	Ouédraogo, Césaire T: 2 articles (01/2021 - 01/2017)
7.	Ponnuraj, Nagendraprabhu: 2 articles (01/2021 - 01/2019)
8.	Vega-Rodriguez, Widaliz: 2 articles (01/2021 - 01/2019)
9.	Wessells, K Ryan: 2 articles (01/2021 - 01/2017)
10.	Kalnoky, Michael: 2 articles (01/2020 - 01/2017)

Related Diseases

1.	Persistent Infection 01/01/2017 - "Using three genetically engineered HSV-1 TK- mutants and two strains of nude mice deficient in T cells, we found that all three HSV-1 TK- mutants can efficiently establish persistent infection in the brain stem and trigeminal ganglion and detected glycoprotein C, a true late viral antigen, in brainstem neurons. " 02/01/1987 - "Analysis of HSV glycoprotein C production and viral DNA showed that treatment with 100 microM DHPG eliminated HSV production, curing the cell line of HSV persistent infection."
2.	Pseudorabies 03/31/1999 - "Intradermal vaccination with plasmid DNA encoding envelope glycoprotein C (gC) of pseudorabies virus (PrV) conferred protection of pigs against Aujeszky's disease when challenged with strain 75V19, but proved to be inadequate for protection against the highly virulent strain NIA-3. "
3.	Infections 01/01/1995 - "Pulse-chase studies of glycoprotein C processing showed a reduction in rate at 7.5 h post infection and a significant block in processing at 10.5 h post infection for 424 and 490 but not KOS. " 03/01/2012 - "PLZF or Slug stimulated productive infection 20- or 5-fold, respectively, and Slug stimulated the late glycoprotein C promoter more than 10-fold. " 01/01/2007 - "No such infection was observed for EHV-4 in RK cells expressing EHV-1 glycoprotein C. " 12/01/2003 - "The recombination of two BoHV-1 mutants lacking either glycoprotein C (gC(-)/gE(+)) or E (gC(+)/gE(-)) was investigated after inoculation of cattle by the natural route of infection. " 09/01/2003 - "One HSV-1 late gene which is highly dependent on ICP27 during infection is that encoding the glycoprotein C (gC). "
4.	Glioma (Gliomas) 02/01/2010 - "In this study, we have inserted a human glioma-specific peptide sequence (denoted as MG11) into a peptide display HSV-1 amplicon vector replacing the heparan sulfate-binding domain of glycoprotein C (gC). " 11/12/2002 - "In the first stage of engineering a herpes simplex virus (HSV)-1 that specifically targets human malignant glioma cells, we constructed a recombinant virus designated R5111 in which we have ablated the binding sites for sulfated proteoglycans in glycoproteins B and C, replaced the amino-terminal 148 aa in glycoprotein C by IL-13 flanked at its amino terminus with a signal peptide, and inserted a second copy of IL-13 after the amino acid 24 of glycoprotein D. "
5.	Necrosis 01/01/1993 - "Induction of bilateral retinal necrosis in mice by unilateral intracameral inoculation of a glycoprotein-C deficient clinical isolate of herpes simplex virus type 1." 01/01/1993 - "Previous studies suggested that a major envelope glycoprotein of HSV-1, glycoprotein C (gC), is required for retinal necrosis. "

Related Drugs and Biologics

1.	Viral DNA
2.	DNA (Deoxyribonucleic Acid)
3.	3,4-dihydroxyphenylglycol
4.	Proteins (Proteins, Gene)
5.	Glycoproteins (Glycoprotein)
6.	Peptides (Polypeptides)
7.	Heparitin Sulfate (Heparan Sulfate)
8.	DNA-Binding Proteins (DNA Binding Protein)
9.	Trans-Activators (Trans-Acting Factor)
10.	Retinaldehyde (Retinal)

Related Therapies and Procedures

1.	Immunomodulation
2.	Caloric Restriction